[{"id":"531ae39e-01c4-436e-9a46-eb2502847532","acronym":"LuminICE-203","url":"https://clinicaltrials.gov/study/NCT05883449","created_at":"2023-06-01T14:07:49.446Z","updated_at":"2024-07-02T16:35:00.909Z","phase":"Phase 2","brief_title":"Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL","source_id_and_acronym":"NCT05883449 - LuminICE-203","lead_sponsor":"Affimed GmbH","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • acimtamig (AFM13) • AFM13/AB-101 • AlloNK (GCC4001)"],"overall_status":"Recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-05-27"},{"id":"498a1e42-e7ba-4c45-b9ea-df2809619942","acronym":"","url":"https://clinicaltrials.gov/study/NCT04074746","created_at":"2021-01-18T19:57:28.222Z","updated_at":"2024-07-02T16:35:08.805Z","phase":"Phase 1/2","brief_title":"Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas","source_id_and_acronym":"NCT04074746","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • acimtamig (AFM13) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/18/2020","start_date":" 07/18/2020","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 04/15/2025","study_completion_date":" 04/15/2025","last_update_posted":"2024-04-18"},{"id":"ac11fef2-00de-4d70-b80b-5c5887b96c6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05817058","created_at":"2023-08-14T10:11:11.877Z","updated_at":"2024-07-02T16:35:14.822Z","phase":"Phase 1","brief_title":"First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05817058","lead_sponsor":"Affimed GmbH","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFM28"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-03-13"},{"id":"d0dd1a36-47bd-4287-8d50-49e2b6a8ce74","acronym":"REDIRECT","url":"https://clinicaltrials.gov/study/NCT04101331","created_at":"2021-01-18T20:03:46.762Z","updated_at":"2024-07-02T16:35:21.105Z","phase":"Phase 2","brief_title":"Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides","source_id_and_acronym":"NCT04101331 - REDIRECT","lead_sponsor":"Affimed GmbH","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e acimtamig (AFM13)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 11/13/2019","start_date":" 11/13/2019","primary_txt":" Primary completion: 05/11/2022","primary_completion_date":" 05/11/2022","study_txt":" Completion: 01/11/2024","study_completion_date":" 01/11/2024","last_update_posted":"2024-02-02"},{"id":"da16b01c-0b95-4070-b26b-6e577c2505fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT06087770","created_at":"2023-10-18T16:14:20.322Z","updated_at":"2024-07-02T16:35:26.014Z","phase":"Phase 1","brief_title":"Clinical Study of SM3321 With Solid Tumors","source_id_and_acronym":"NCT06087770","lead_sponsor":"Beijing StarMab Biomed Technology Ltd","biomarkers":" CD4 • IL2","pipe":"","alterations":" ","tags":["CD4 • IL2"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 12/07/2023","start_date":" 12/07/2023","primary_txt":" Primary completion: 08/19/2025","primary_completion_date":" 08/19/2025","study_txt":" Completion: 10/14/2025","study_completion_date":" 10/14/2025","last_update_posted":"2023-12-18"},{"id":"a6ff77bf-43f0-491c-b636-703839e573f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05109442","created_at":"2021-11-05T12:53:17.433Z","updated_at":"2024-07-02T16:35:38.810Z","phase":"Phase 1/2","brief_title":"Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers","source_id_and_acronym":"NCT05109442","lead_sponsor":"Affimed GmbH","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • EGFR wild-type • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • EGFR wild-type • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • AFM24"],"overall_status":"Recruiting","enrollment":" Enrollment 148","initiation":"Initiation: 11/19/2021","start_date":" 11/19/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-08-29"},{"id":"d4a29523-440e-4515-8e78-e0bd662648f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04259450","created_at":"2021-01-18T20:42:00.797Z","updated_at":"2024-07-02T16:35:39.230Z","phase":"Phase 1/2","brief_title":"Study to Assess AFM24 in Advanced Solid Cancers","source_id_and_acronym":"NCT04259450","lead_sponsor":"Affimed GmbH","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFM24"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 04/07/2020","start_date":" 04/07/2020","primary_txt":" Primary completion: 07/12/2023","primary_completion_date":" 07/12/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-08-23"},{"id":"d43c68c1-dadc-42f9-b0fe-bed6acf3f2ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT03192202","created_at":"2021-01-18T15:44:38.585Z","updated_at":"2024-07-02T16:35:42.482Z","phase":"Phase 1/2","brief_title":"AFM13 in Relapsed/Refractory Cutaneous Lymphomas","source_id_and_acronym":"NCT03192202","lead_sponsor":"Ahmed Sawas","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e acimtamig (AFM13)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 07/17/2017","start_date":" 07/17/2017","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2023-07-20"},{"id":"abe763ae-9852-4c0b-9319-aa8d0aee94b7","acronym":"GHSG-AFM13","url":"https://clinicaltrials.gov/study/NCT02321592","created_at":"2021-01-18T11:00:36.381Z","updated_at":"2024-07-02T16:36:38.749Z","phase":"Phase 2","brief_title":"GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT02321592 - GHSG-AFM13","lead_sponsor":"University of Cologne","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e acimtamig (AFM13)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2020-11-13"},{"id":"2750cb6c-3505-4f58-a13a-1114f6ddbdb0","acronym":"KEYNOTE-206","url":"https://clinicaltrials.gov/study/NCT02665650","created_at":"2021-01-18T12:59:40.864Z","updated_at":"2025-02-25T16:04:16.597Z","phase":"Phase 1b","brief_title":"Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","source_id_and_acronym":"NCT02665650 - KEYNOTE-206","lead_sponsor":"Affimed GmbH","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • acimtamig (AFM13)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2019-05-16"}]